Phase II trial of SOM230 (pasireotide LAR) in patients with unresectable hepatocellular carcinoma

Phase II trial of SOM230 (pasireotide LAR) in patients with unresectable hepatocellular carcinoma

Lynn G Feun,¹ Medhi Wangpaichitr,² Ying-Ying Li,¹ Deukwoo Kwon,³ Stephen P Richman,¹ Peter J Hosein,¹ Niramol Savaraj¹,² ¹Department of Medicine, Medical Oncology, Sylvester Comprehensive Cancer Center, University of Mi...

Full description

Bibliographic Details
Main Authors:	Feun LG, Wangpaichitr M, Li YY, Kwon D, Richman SP, Hosein PJ, Savaraj N
Format:	Article
Language:	English
Published:	Dove Medical Press 2018-01-01
Series:	Journal of Hepatocellular Carcinoma
Subjects:	pasireotide hepatocellular carcinoma
Online Access:	https://www.dovepress.com/phase-ii-trial-of-som230-pasireotide-lar-in-patients-with-unresectable-peer-reviewed-article-JHC

Similar Items

Successful Control of Hypoglycemia with Pasireotide LAR in a Patient with Inappropriate Insulin Secretion
by: Rouland A, et al.
Published: (2021-02-01)

The Effect of 6 Months’ Treatment With Pasireotide LAR on Glucose Metabolism in Patients With Resistant Acromegaly in Real-World Clinical Settings
by: Przemysław Witek, et al.
Published: (2021-03-01)

Pasireotide-LAR in acromegaly patients treated with a combination therapy: a real-life study
by: Hélène Lasolle, et al.
Published: (2019-10-01)

Infertility as the onset of Cushing’s disease: is pasireotide a treatment option?
by: Valea Ana, et al.
Published: (2015-08-01)

Pasireotide: A new option for treatment of acromegaly
by: Filiz Eksi Haydardedeoglu, et al.
Published: (2020-06-01)

Risk factors and management of pasireotide-associated hyperglycemia in acromegaly
by: Mônica R Gadelha, et al.
Published: (2020-12-01)

Pasireotide after Surgery for Persistent Cushing’s Disease
by: Dan Nicolae PADURARU, et al.
Published: (2019-12-01)

Successful debulking of plurihormonal pituitary macroadenoma with long‐acting pasireotide and dopamine agonist combination therapy
by: Terri W. Jerkins, et al.
Published: (2019-03-01)

Rapid response of Nelson’s syndrome to pasireotide in radiotherapy-naive patient
by: Xin He, et al.
Published: (2020-11-01)

Efficacy of combined treatment with pasireotide, pegvisomant and cabergoline in an acromegalic patient resistant to other treatments: a case report
by: A. Ciresi, et al.
Published: (2018-01-01)

Loss of efficacy of pasireotide after its re-administration: is there a reason why?
by: Stylianos Mandanas, et al.
Published: (2016-12-01)

AIP-mutated acromegaly resistant to first-generation somatostatin analogs: long-term control with pasireotide LAR in two patients
by: Adrian F Daly, et al.
Published: (2019-04-01)

Phase I dose-escalation study of long-acting pasireotide in patients with neuroendocrine tumors
by: Yao JC, et al.
Published: (2017-06-01)

Cardiometabolic Risk in Acromegaly: A Review With a Focus on Pasireotide
by: Soraya Puglisi, et al.
Published: (2020-02-01)

Pasireotide: a novel treatment for patients with acromegaly
by: Cuevas-Ramos D, et al.
Published: (2016-01-01)

A Practical and Total Synthesis of Pasireotide: Synthesis of Cyclic Hexapeptide via a Three-Component Condensation
by: Chunying Ma, et al.
Published: (2019-06-01)

Incretin Response to Mixed Meal Challenge in Active Cushing’s Disease and after Pasireotide Therapy
by: Barbot, M., et al.
Published: (2022)

Serial follow-up of presurgical treatment using pasireotide long-acting release with or without octreotide long-acting release for naïve active acromegaly
by: Jan-Shun Chang, et al.
Published: (2016-06-01)

Evaluation of the Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Inadequately Controlled With First-Generation Somatostatin Analogs
by: Mônica Gadelha, et al.
Published: (2020-02-01)

Safety and Efficacy of Subcutaneous Pasireotide in Patients With Cushing's Disease: Results From an Open-Label, Multicenter, Single-Arm, Multinational, Expanded-Access Study
by: Maria Fleseriu, et al.
Published: (2019-07-01)

Gender-Specific Efficacy Revealed by Head-to-Head Comparison of Pasireotide and Octreotide in a Representative In Vivo Model of Nonfunctioning Pituitary Tumors
by: Sebastian Gulde, et al.
Published: (2021-06-01)

Liver Transplantation in the Treatment of Unresectable Hepatocellular Carcinoma in the Absence of Liver Cirrhosis
by: O. D. Olisov, et al.
Published: (2018-09-01)

Lenvatinib as the key component of first-line therapy for patients with unresectable hepatocellular carcinoma
by: L. V. Bolotina
Published: (2020-11-01)

Y-90 microshperes in the treatment of unresectable hepatocellular carcinoma
by: Al-Kalbani Abdullah, et al.
Published: (2008-01-01)

Unresectable hepatocellular carcinoma: new opportunities and prospects for therapy
by: Dzhamal T Abdurakhmanov, et al.
Published: (2019-06-01)

Clinical impact of lenvatinib in patients with unresectable hepatocellular carcinoma who received sorafenib
by: Yen-Yang Chen, et al.
Published: (2020-11-01)

Yttrium-90 resin microspheres as an adjunct to sorafenib in patients with unresectable hepatocellular carcinoma
by: Mahvash A, et al.
Published: (2016-02-01)

Combined versus single locoregional therapy in the treatment of unresectable hepatocellular carcinoma
by: Moustafa H.M. Othman, et al.
Published: (2014-06-01)

Octreotide and Pasireotide Combination Treatment in Somatotroph Tumor Cells: Predominant Role of SST<sub>2</sub> in Mediating Ligand Effects
by: Jessica Amarù, et al.
Published: (2021-04-01)

Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date
by: Personeni N, et al.
Published: (2019-01-01)

Factors Predicting Survival after Transarterial Chemoembolization of Unresectable Hepatocellular Carcinoma
by: Farina M. Hanif, et al.
Published: (2014-10-01)

Outcome of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma
by: Hadeel A Helmi, et al.
Published: (2020-01-01)

Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma
by: Francesco Tovoli, et al.
Published: (2021-06-01)

Efficacy And Safety Of Raltitrexed Plus Oxaliplatin-Based Transarterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma
by: Shao W, et al.
Published: (2019-11-01)

Pasireotide‐induced hyperglycemia in a patient with Cushing's disease: Potential use of sodium‐glucose cotransporter 2 inhibitor and glucagon‐like peptide‐1 receptor agonist for treatment
by: Masato Shikata, et al.
Published: (2020-12-01)

Yttrium-90 radioembolization of unresectable hepatocellular carcinoma – a single center experience
by: Meyer C, et al.
Published: (2017-09-01)

Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma: Preliminary Toxicity and Activity Data in Dogs
by: Laura Marconato, et al.
Published: (2020-05-01)

Role of triphasic computed tomography in prediction of response to transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma patients
by: Ahmed A.E Hassan Desoky, et al.
Published: (2019-01-01)

Severe hepatocytolisis syndrome - a challenge in medical therapy of Cushing’s disease
by: Valea Ana, et al.
Published: (2015-08-01)

Chinese herbal medicine, Jianpi Ligan decoction, improves prognosis of unresectable hepatocellular carcinoma after transarterial chemoembolization: a retrospective study
by: Tang CW, et al.
Published: (2016-08-01)